Ryan Halsted
Stock Analyst at RBC Capital
(3.17)
# 2,547
Out of 4,988 analysts
102
Total ratings
56.2%
Success rate
4.6%
Average return
Main Sectors:
Stocks Rated by Ryan Halsted
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Reiterated: Buy | $282 | $278.06 | +1.42% | 6 | Sep 16, 2026 | |
| MCK McKesson | Reiterated: Hold | $845 | $874.65 | -3.39% | 2 | Sep 14, 2026 | |
| COR Cencora | Reiterated: Hold | $330 | $308.78 | +6.87% | 2 | Sep 4, 2026 | |
| PHR Phreesia | Reiterated: Buy | $19 | $10.04 | +89.24% | 6 | Sep 3, 2026 | |
| HQY HealthEquity | Reiterated: Buy | $108 | $95.14 | +13.52% | 4 | Aug 27, 2026 | |
| WAY Waystar Holding | Reiterated: Buy | $44 | $25.66 | +71.47% | 9 | Aug 27, 2026 | |
| CAH Cardinal Health | Initiated Coverage: Buy | $276 | $225.38 | +22.46% | 1 | Aug 19, 2026 | |
| DOCS Doximity | Reiterated: Buy | $28 | $26.11 | +7.24% | 10 | Aug 6, 2026 | |
| EVH Evolent Health | Reiterated: Hold | $3 | $3.69 | -18.70% | 6 | Aug 6, 2026 | |
| PRVA Privia Health Group | Reiterated: Buy | $31 | $19.85 | +56.17% | 8 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $24 | $18.73 | +28.14% | 10 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $53 → $46 | $31.64 | +45.39% | 7 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $185 | $164.11 | +12.73% | 5 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $221 → $247 | $266.42 | -7.29% | 6 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $484 → $692 | $612.33 | +13.01% | 6 | Jul 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $24 | $21.47 | +11.78% | 5 | Jul 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $11.45 | n/a | 4 | Jan 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $38.27 | n/a | 1 | Oct 6, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $77.76 | n/a | 1 | Sep 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $22 | $173.91 | n/a | 3 | May 12, 2016 |
Charles River Laboratories International
Sep 16, 2026
Reiterated: Buy
Price Target: $282
Current: $278.06
Upside: +1.42%
McKesson
Sep 14, 2026
Reiterated: Hold
Price Target: $845
Current: $874.65
Upside: -3.39%
Cencora
Sep 4, 2026
Reiterated: Hold
Price Target: $330
Current: $308.78
Upside: +6.87%
Phreesia
Sep 3, 2026
Reiterated: Buy
Price Target: $19
Current: $10.04
Upside: +89.24%
HealthEquity
Aug 27, 2026
Reiterated: Buy
Price Target: $108
Current: $95.14
Upside: +13.52%
Waystar Holding
Aug 27, 2026
Reiterated: Buy
Price Target: $44
Current: $25.66
Upside: +71.47%
Cardinal Health
Aug 19, 2026
Initiated Coverage: Buy
Price Target: $276
Current: $225.38
Upside: +22.46%
Doximity
Aug 6, 2026
Reiterated: Buy
Price Target: $28
Current: $26.11
Upside: +7.24%
Evolent Health
Aug 6, 2026
Reiterated: Hold
Price Target: $3
Current: $3.69
Upside: -18.70%
Privia Health Group
Aug 6, 2026
Reiterated: Buy
Price Target: $31
Current: $19.85
Upside: +56.17%
Aug 6, 2026
Reiterated: Buy
Price Target: $24
Current: $18.73
Upside: +28.14%
Aug 5, 2026
Reiterated: Buy
Price Target: $53 → $46
Current: $31.64
Upside: +45.39%
Jul 30, 2026
Reiterated: Buy
Price Target: $185
Current: $164.11
Upside: +12.73%
Jul 28, 2026
Reiterated: Buy
Price Target: $221 → $247
Current: $266.42
Upside: -7.29%
Jul 23, 2026
Reiterated: Buy
Price Target: $484 → $692
Current: $612.33
Upside: +13.01%
Jul 22, 2026
Reiterated: Hold
Price Target: $24
Current: $21.47
Upside: +11.78%
Jan 12, 2017
Upgraded: Buy
Price Target: n/a
Current: $11.45
Upside: n/a
Oct 6, 2016
Reiterated: Hold
Price Target: n/a
Current: $38.27
Upside: n/a
Sep 9, 2016
Reiterated: Hold
Price Target: n/a
Current: $77.76
Upside: n/a
May 12, 2016
Reiterated: Hold
Price Target: $22
Current: $173.91
Upside: n/a